News

Filter

Current filters:

StallergenesOncology

26 to 35 of 96529 results

New WikiLeaks revelations on Trans-Pacific Trade Pact Text

17-10-2014

Access to affordable cancer treatments in the USA and 11 other countries would be delayed for years if…

Asia-PacificPatents & Trade marksPharmaceuticalPoliticsUSA

Pharmacyclics and Roche research Imbruvica and Gazyva

Pharmacyclics and Roche research Imbruvica and Gazyva

17-10-2014

USA-based biopharma company Pharmacyclics has entered into a master clinical drug supply agreement with…

GazyvaImbruvicaOncologyPharmaceuticalPharmacyclicsResearchRocheUSA

Virax to acquire AKTivate and deep AKT inhibitor portfolio

17-10-2014

Australian biotechnology company Virax Holdings will acquire US oncology company AKTivate Therapeutics…

AKTivate TherapeuticsBiotechnologyMergers & AcquisitionsOncologyPathway OncologyVirax Holdings

ACCC proposes to strengthen new individual reporting in Australian pharmaceutical code

17-10-2014

The Australian Competition and Consumer Commission (ACCC) is proposing to grant conditional authorization…

AustraliaMarkets & MarketingPharmaceuticalRegulation

Selecta, JDRF and Sanofi collaborate to develop SVP for type 1 diabetes

Selecta, JDRF and Sanofi collaborate to develop SVP for type 1 diabetes

17-10-2014

US clinical-stage biopharma company Selecta Biosciences and JDRF have extended their joint research collaboration…

BiotechnologyDiabetesFranceResearchSanofiSelecta BiosciencesUSA

US FDA panel votes to keep Chantix black box warning; staffers recommend secukinumab

US FDA panel votes to keep Chantix black box warning; staffers recommend secukinumab

17-10-2014

The US Food and Drug Administration's advisory panel has voted to keep a black box warning on US pharma…

ChantixNovartisPfizerPharmaceuticalRegulationsecukinumabUSA

NICE reverses guidance on Novartis’ Glivec for GIST

NICE reverses guidance on Novartis’ Glivec for GIST

17-10-2014

UK health costs watchdog the National Institute for Health and Care Excellence (NICE) has issued new…

GlivecNovartisOncologyPharmaceuticalPricingRegulationUK

Aduro expands deal with Janssen to lung cancer; worth up to $817 million

Aduro expands deal with Janssen to lung cancer; worth up to $817 million

17-10-2014

Privately-held US cancer immunotherapy developer Aduro BioTech has entered into its second agreement…

Aduro BioTechBiotechnologyGlobalJanssen BiotechJohnson & JohnsonLicensingOncologyResearch

26 to 35 of 96529 results

Parexel

Parexel

Back to top